Navigation Links
WuXi PharmaTech to Present at 27th Annual J.P. Morgan Healthcare Conference
Date:1/6/2009

SHANGHAI, China, Jan. 6 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device research and development outsourcing company with operations in China and the United States, today announced that Dr. Ge Li, the Company's Chairman and Chief Executive Officer, will present at the 27th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2009, at 4:30 pm Pacific Standard Time.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

The Company will broadcast its presentation. The public may access the broadcast through the Investor Relations section of the Company's web site: http://www.wuxiapptec.com .

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com .

    For more information, please contact:

     Ronald Aldridge
     Director of Investor Relations
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +1-215-218-5515
     Email: Ron_Aldridge@wuxiapptec.com

     Juliane Snowden
     Vice President of Investor Relations
     Burns McClellan
     Tel:   +1-212-213-0006
     Email: Jsnowden@burnsmc.com

     Web:http://www.wuxiapptec.com

'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmatech 2.0: Introducing Pharmatech Oncology
2. WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services
3. WuXi PharmaTech Appoints Ying Han to Its Board of Directors
4. WuXi PharmaTech Announces Third Quarter 2008 Results
5. WuXi PharmaTech Signs New Collaboration Agreement With Pfizer
6. WuXi PharmaTech Schedules Third Quarter 2008 Earnings Release on Wednesday, November 12, 2008
7. WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance
8. WuXi PharmaTech Appoints Jeff Leng to Its Board of Directors
9. Matthew B. Wiener, CEO of Pharmatech, Inc., Is Awarded the Cancer Leadership Award From the Colorado Cancer Coalition
10. WuXi PharmaTech (NYSE:WX) Maintains Original Strategy to Provide Toxicology Services in China
11. WuXi PharmaTech Promotes Dr. Rujian Ma to VP of Synthetic Chemistry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... 23, 2016  The Prostate Cancer Foundation (PCF) is pleased to ... faster cures for prostate cancer. Members of the Class of 2016 were selected ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... NC (PRWEB) , ... June 23, 2016 , ... In ... University Hospital in Denmark detail how a patient who developed lymphedema after being treated ... tissue. The results could change the paradigm for dealing with this debilitating, frequent side ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest features ... will also be presenting a scientific poster on Disrupting Clinical Trials in The ...
Breaking Biology Technology:
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/15/2016)... , April 15, 2016  A new partnership ... more accurate underwriting decisions in a fraction of ... competitively priced and high-value life insurance policies to ... With Force Diagnostics, rapid testing (A1C, ... data readings (blood pressure, weight, pulse, BMI, and ...
(Date:3/31/2016)... RATON, Florida , March 31, 2016 ... LEGX ) ("LegacyXChange" or the "Company") ... for potential users of its soon to be launched ... video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide ... the use of DNA technology to an industry that ...
Breaking Biology News(10 mins):